|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 146.00 GBX | 0.00% |
|
+0.69% | +14.06% |
| 06-02 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 | |
| 05-26 | Diaceutics PLC Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 0.78 | 0.77 | -3.99 | -3.23 | 0.05 | |||||
Return on Total Capital | 0.83 | 0.84 | -4.4 | -3.7 | 0.07 | |||||
Return On Equity % | 1.39 | 1.74 | -4.19 | -4.22 | 0.24 | |||||
Return on Common Equity | 1.39 | 1.74 | -4.19 | -4.22 | 0.24 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 76.97 | 85.83 | 83.15 | 87.91 | 81.9 | |||||
SG&A Margin | 74.42 | 83.47 | 96.14 | 95.6 | 82.45 | |||||
EBITDA Margin % | 10.88 | 10.64 | 0.43 | 1.72 | 10.63 | |||||
EBITA Margin % | 10.27 | 9.89 | -0.25 | 1.2 | 10.2 | |||||
EBIT Margin % | 3.94 | 2.95 | -12.73 | -7.63 | 0.11 | |||||
Income From Continuing Operations Margin % | 4.02 | 3.71 | -7.37 | -5.3 | 0.25 | |||||
Net Income Margin % | 4.02 | 3.71 | -7.37 | -5.3 | 0.25 | |||||
Net Avail. For Common Margin % | 4.02 | 3.71 | -7.37 | -5.3 | 0.25 | |||||
Normalized Net Income Margin | 2.07 | 1.81 | -6.43 | -3.71 | 0.49 | |||||
Levered Free Cash Flow Margin | -39.79 | -1.82 | -4.98 | -7.3 | -10.62 | |||||
Unlevered Free Cash Flow Margin | -39.39 | -1.43 | -4.81 | -7.2 | -10.52 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.31 | 0.42 | 0.5 | 0.68 | 0.78 | |||||
Fixed Assets Turnover | 11.78 | 9.24 | 11.88 | 17.98 | 23 | |||||
Receivables Turnover (Average Receivables) | 2.26 | 2.54 | 2.6 | 2.61 | 2.23 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 11.41 | 8.23 | 6.4 | 3.8 | 3.43 | |||||
Quick Ratio | 11.24 | 8.07 | 6.11 | 3.66 | 3.3 | |||||
Operating Cash Flow to Current Liabilities | 0.22 | 1.36 | 0.3 | 0.08 | 0.14 | |||||
Days Sales Outstanding (Average Receivables) | 161.58 | 143.87 | 140.2 | 140.25 | 163.9 | |||||
Average Days Payable Outstanding | 55.64 | 84.02 | 83.37 | 107.41 | 72.23 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 3.84 | 3.13 | 2.95 | 2.66 | 2.85 | |||||
Total Debt / Total Capital | 3.7 | 3.03 | 2.87 | 2.59 | 2.77 | |||||
LT Debt/Equity | 3.16 | 2.83 | 2.6 | 2.28 | 2.18 | |||||
Long-Term Debt / Total Capital | 3.04 | 2.75 | 2.52 | 2.22 | 2.12 | |||||
Total Liabilities / Total Assets | 9.69 | 11.9 | 11.99 | 18.02 | 19.05 | |||||
EBIT / Interest Expense | 6.25 | 4.79 | -45.73 | -45.46 | 0.74 | |||||
EBITDA / Interest Expense | 17.8 | 18.61 | 3.86 | 13.07 | 75.45 | |||||
(EBITDA - Capex) / Interest Expense | 11.38 | 17.06 | 1.97 | 11.22 | 74.22 | |||||
Total Debt / EBITDA | 1 | 0.6 | 4.73 | 1.5 | 0.26 | |||||
Net Debt / EBITDA | -11.57 | -8.29 | -60.64 | -16.55 | -1.41 | |||||
Total Debt / (EBITDA - Capex) | 1.56 | 0.65 | 9.27 | 1.75 | 0.27 | |||||
Net Debt / (EBITDA - Capex) | -18.1 | -9.04 | -118.94 | -19.28 | -1.44 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 9.82 | 39.88 | 21.51 | 35.69 | 19.53 | |||||
Gross Profit, 1 Yr. Growth % | 13.41 | 36.86 | 17.71 | 43.46 | 11.35 | |||||
EBITDA, 1 Yr. Growth % | 256.94 | 36.85 | -95.09 | 441.18 | 640.04 | |||||
EBITA, 1 Yr. Growth % | 265.31 | 34.71 | -103.06 | -752.54 | 917.92 | |||||
EBIT, 1 Yr. Growth % | -303.7 | 4.55 | -624.87 | -18.65 | -101.75 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 113.31 | 29.06 | -341.16 | -2.46 | -105.7 | |||||
Net Income, 1 Yr. Growth % | 113.31 | 29.06 | -341.16 | -2.46 | -105.7 | |||||
Normalized Net Income, 1 Yr. Growth % | -257.14 | 22.08 | -532.27 | -21.74 | -115.83 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 94.55 | 27.29 | -346.77 | -2.56 | -105.44 | |||||
Accounts Receivable, 1 Yr. Growth % | 31.05 | 19.59 | 17.41 | 50.67 | 33.02 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 794.54 | -1.74 | -9.23 | -11.64 | -0.83 | |||||
Total Assets, 1 Yr. Growth % | 3.43 | 7.2 | -3.96 | 4.91 | 2.85 | |||||
Tangible Book Value, 1 Yr. Growth % | -10.4 | -2.05 | -7.08 | -4.23 | -0.18 | |||||
Common Equity, 1 Yr. Growth % | 1.02 | 4.59 | -4.06 | -2.28 | 1.56 | |||||
Cash From Operations, 1 Yr. Growth % | 125.3 | 794.04 | -74.27 | -50.34 | 81.11 | |||||
Capital Expenditures, 1 Yr. Growth % | 312.41 | -67.08 | -32.8 | -20 | -29 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -13.22 | -93.61 | 232.89 | 98.91 | 73.81 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -13.65 | -94.91 | 307.42 | 103.15 | 74.78 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 1.85 | 23.94 | 30.37 | 28.41 | 27.35 | |||||
Gross Profit, 2 Yr. CAGR % | 2.02 | 33.01 | 26.93 | 29.95 | 26.39 | |||||
EBITDA, 2 Yr. CAGR % | -18.63 | 121.01 | -74.07 | -48.44 | 532.84 | |||||
EBITA, 2 Yr. CAGR % | -20.28 | 121.83 | -79.7 | -55.33 | 715.01 | |||||
EBIT, 2 Yr. CAGR % | -48.68 | 45.93 | 134.25 | 106.63 | -88.06 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 18.72 | 65.92 | 76.42 | 53.37 | -76.43 | |||||
Net Income, 2 Yr. CAGR % | 18.72 | 65.92 | 76.42 | 53.37 | -76.43 | |||||
Normalized Net Income, 2 Yr. CAGR % | -49.96 | 38.51 | 129.72 | 83.93 | -64.8 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 3.17 | 57.37 | 77.24 | 55.07 | -76.97 | |||||
Accounts Receivable, 2 Yr. CAGR % | 6.84 | 25.19 | 18.5 | 33.01 | 41.57 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 300.09 | 196.48 | -5.56 | -10.44 | -6.39 | |||||
Total Assets, 2 Yr. CAGR % | 41.85 | 5.3 | 1.47 | 0.38 | 3.88 | |||||
Tangible Book Value, 2 Yr. CAGR % | 22.28 | -6.32 | -4.6 | -5.67 | -2.23 | |||||
Common Equity, 2 Yr. CAGR % | 42.1 | 2.79 | 0.17 | -3.18 | -0.38 | |||||
Cash From Operations, 2 Yr. CAGR % | -4.88 | 348.8 | 51.66 | -64.26 | -5.17 | |||||
Capital Expenditures, 2 Yr. CAGR % | 138.89 | 16.52 | -52.96 | -26.68 | -24.63 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 38.62 | -76.45 | -53.87 | 157.32 | 85.94 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 41.38 | -79.03 | -54.46 | 187.69 | 88.43 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 10.36 | 13.21 | 23.13 | 32.12 | 25.37 | |||||
Gross Profit, 3 Yr. CAGR % | 16.42 | 17.53 | 27.7 | 32.21 | 23.43 | |||||
EBITDA, 3 Yr. CAGR % | -0.14 | -3.23 | -37.86 | -28.61 | 25.31 | |||||
EBITA, 3 Yr. CAGR % | -1.24 | -5.04 | -46.81 | -35.46 | 26.65 | |||||
EBIT, 3 Yr. CAGR % | -26.86 | -34.94 | 123.59 | 64.65 | -57.87 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -3.91 | 22.07 | 87.94 | 44.79 | -48.83 | |||||
Net Income, 3 Yr. CAGR % | -3.91 | 22.07 | 87.94 | 44.79 | -48.83 | |||||
Normalized Net Income, 3 Yr. CAGR % | -24.7 | -32.64 | 102.41 | 60.44 | -18.8 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -22.33 | 10.65 | 82.83 | 45.19 | -49.23 | |||||
Accounts Receivable, 3 Yr. CAGR % | 19.71 | 10.93 | 22.54 | 28.38 | 33.01 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 206.43 | 150.56 | 99.82 | -7.63 | -7.35 | |||||
Total Assets, 3 Yr. CAGR % | 79.29 | 29.21 | 2.12 | 2.6 | 1.2 | |||||
Tangible Book Value, 3 Yr. CAGR % | 132.51 | 13.57 | -6.57 | -4.48 | -3.87 | |||||
Common Equity, 3 Yr. CAGR % | 149.11 | 28.3 | 0.45 | -0.65 | -1.62 | |||||
Cash From Operations, 3 Yr. CAGR % | -15.78 | 100.74 | 73.05 | 4.53 | -38.61 | |||||
Capital Expenditures, 3 Yr. CAGR % | 109.77 | 23.39 | -3.01 | -43.85 | -27.46 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 25.63 | -50.29 | -43.05 | -24.92 | 125.78 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 28.16 | -53.31 | -43.63 | -25.03 | 143.66 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 24.89 | 21.49 | 17.97 | 19.06 | 24.8 | |||||
Gross Profit, 5 Yr. CAGR % | 32.23 | 27.92 | 23.71 | 22.35 | 27.17 | |||||
EBITDA, 5 Yr. CAGR % | 7.64 | 17.48 | -41.77 | -24.77 | 57.24 | |||||
EBITA, 5 Yr. CAGR % | 6.5 | 16.21 | -47.55 | -29.77 | 58.48 | |||||
EBIT, 5 Yr. CAGR % | -9.02 | -8.6 | 16.51 | 3.29 | -30.75 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -5.57 | 1.77 | 22.52 | 33.74 | -18.09 | |||||
Net Income, 5 Yr. CAGR % | -5.57 | 1.77 | 22.52 | 33.74 | -18.09 | |||||
Normalized Net Income, 5 Yr. CAGR % | -10.06 | -6.4 | 17.64 | 0.67 | 0.54 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -82.65 | -81.02 | 8.04 | 26.64 | -20.18 | |||||
Accounts Receivable, 5 Yr. CAGR % | 29.46 | 38.01 | 19.22 | 19.28 | 29.83 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 157.33 | 111.54 | 91.37 | 66.03 | 47.54 | |||||
Total Assets, 5 Yr. CAGR % | 67.24 | 54.44 | 42.78 | 16.8 | 2.82 | |||||
Tangible Book Value, 5 Yr. CAGR % | 95.01 | 76.66 | 62.81 | 5.44 | -4.86 | |||||
Common Equity, 5 Yr. CAGR % | 109.29 | 86.63 | 73.03 | 14.64 | 0.12 | |||||
Cash From Operations, 5 Yr. CAGR % | -3.3 | 27.14 | 6.56 | 0.66 | 36.04 | |||||
Capital Expenditures, 5 Yr. CAGR % | 109.73 | 31.15 | 15.35 | 0.2 | -12.32 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 76.04 | -20.25 | -15.85 | -4.05 | -8.58 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 70.33 | -24.88 | -15.27 | -3.37 | -8.66 |
- Stock Market
- Stocks
- DXRX Stock
- Financials Diaceutics PLC
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















